You are here

  • Home
  • Archive
  • Volume 7, Issue 2
  • Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis

Article metrics

Article menu

Download PDFPDF

XML
Rheumatoid arthritis
Original research
Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis

 

Online download statistics by month:

Online download statistics by month: May 2021 to March 2024

AbstractFullPdf
May 2021957935401
Jun 2021354341107
Jul 202115214266
Aug 202115715046
Sep 20211019940
Oct 2021878360
Nov 2021656548
Dec 2021838731
Jan 2022726727
Feb 2022748128
Mar 2022999727
Apr 202211410737
May 2022848741
Jun 2022878223
Jul 2022504616
Aug 2022999427
Sep 2022888927
Oct 202212311722
Nov 2022545328
Dec 2022414210
Jan 2023535014
Feb 2023999627
Mar 2023686325
Apr 2023585636
May 2023676627
Jun 2023363624
Jul 2023625931
Aug 2023646025
Sep 2023696841
Oct 2023676442
Nov 2023474713
Dec 2023565414
Jan 2024322821
Feb 2024333224
Mar 2024524519
Total380436881495